Compare XPL & XTNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPL | XTNT |
|---|---|---|
| Founded | 1984 | N/A |
| Country | United States | United States |
| Employees | 6 | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.1M | 61.7M |
| IPO Year | 2000 | 2009 |
| Metric | XPL | XTNT |
|---|---|---|
| Price | $0.75 | $0.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $1.20 | $1.00 |
| AVG Volume (30 Days) | 64.3K | ★ 86.3K |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 42.86 | ★ 125.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $53,337,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $9.30 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.54 | $0.39 |
| 52 Week High | $0.98 | $0.95 |
| Indicator | XPL | XTNT |
|---|---|---|
| Relative Strength Index (RSI) | 50.42 | 44.03 |
| Support Level | $0.69 | $0.40 |
| Resistance Level | $0.79 | $0.44 |
| Average True Range (ATR) | 0.03 | 0.03 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 66.67 | 31.94 |
Solitario Resources Corp is an exploration company engaging in acquiring, exploring, and developing zinc properties and other precious metals in safe jurisdictions in North and South America. Its core mineral property assets are: the Florida Canyon zinc project in Peru, the Lik zinc project in Alaska, and the Golden Crest project in South Dakota. Additionally, Solitario holds an interest in the Chambara project in Peru and also has two early-stage projects, the Cat Creek project and the Bright Angel project in Colorado. The company is conducting mineral exploration on its Golden Crest project, the Cat Creek project, and the Bright Angel project on its own.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.